The product Testosterone Cypionate 200 mg/mL, manufactured by Optitropin, underwent independent testing to verify its potency. The sample was submitted by B Ware, an individual consumer with no commercial affiliations, and analyzed by Janoshik Analytical. The results confirmed a measured concentration of 210.10 mg/mL, which is 105.05% of the labeled claim, indicating a slight overdose.
Testing was initiated on 30 August 2024, with the sample received on 4 September 2024, and analysis completed on 6 September 2024. The findings indicate that the tested batch slightly exceeds the labeled specification, reflecting a strong degree of quality control.
This report is published to support harm reduction, transparency, and informed consumer decision-making.
Detailed Report
Product Overview
- Manufacturer: Optitropin
- Product Name: Testosterone Cypionate
- Active Ingredient: Testosterone Cypionate
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #48457
- Testing Ordered: 30 August 2024
- Sample Received: 4 September 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: B Ware (Individual)
- Analysis Paid For By: B Ware (Individual)
Testing Results
| Specification | Measured Concentration | Accuracy | Variance |
|---|---|---|---|
| 200 mg/mL (as per label) | 210.10 mg/mL | 105.05% | +5.05% |
Verification Details
- Verification URL: https://janoshik.com/tests/48457_ERU4MH52IFA1
Evaluation of Consumer-Submitted Testing
The results confirm that the Testosterone Cypionate (200 mg/mL) sample is 5.05% above its labeled claim, with a measured concentration of 210.10 mg/mL. This slight overdose suggests that the manufacturer may have included a marginal excess of the active ingredient, which is often done to compensate for potential degradation over time.
Since this sample was submitted by B Ware, an individual with no ties to resellers, manufacturers, or distributors, the test results are more credible compared to reseller-funded testing, which may selectively provide high-quality batches. However, further independent testing of additional batches is recommended to confirm product consistency.
Conclusion
The analysis of Optitropin’s Testosterone Cypionate 200 mg/mL reveals a slight overdose, with a measured concentration of 210.10 mg/mL, exceeding the label claim by 5.05%. While this suggests strong quality control, ongoing independent batch testing is recommended to ensure consistent dosing.
This report is published to support harm reduction efforts, providing consumers with transparent data to make informed choices regarding anabolic steroid products.
Disclaimer
This report is for educational and harm reduction purposes only. The results pertain solely to the batch tested and may not reflect the quality of other batches. Since this product was tested independently by an individual consumer with no commercial interest, the findings are less likely to be biased. However, readers are encouraged to critically assess these results alongside additional third-party testing. Always consult healthcare professionals and adhere to local regulations before using such products.
